Constantine Farmakidis, MD

Professional Background

Constantine Farmakidis, M.D., is an associate professor of neurology at the University of Kansas Medical Center.

Within The University of Kansas Health System, Dr. Farmakidis sees patients with a broad spectrum of neuromuscular diseases and has special interests in myasthenia gravis and inherited muscle and nerve diseases. He is also active in the electromyography laboratory, where he performs nerve conduction and EMG diagnostic studies.

Dr. Farmakidis serves as associate director of the clinical neurophysiology fellowship, participates in the training of neurology residents, and teaches regularly at the medical school.

Dr. Farmakidis obtained his medical degree and neurology residency training at the University of Rochester School of Medicine. He subsequently completed a fellowship in clinical neurophysiology/EMG at Columbia University. He holds board certifications in neurology, neuromuscular medicine and electrodiagnostic medicine. He is also a member of the Alpha Omega Alpha and Gold Foundation medical honor societies.

• BA, Anthropology, Economics, University of Pennsylvania, Philadelphia, PA
• MD, Medicine, University of Rochester School of Medicine and Dentistry
• Other, Internal Medicine, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, New York
• Other, Neurology, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, New York
• Other, Clinical Neurophysiology/EMG, New York Presbyterian Hospital, Columbia University Medical Center, New York, New York

• Electrodiagnostic Medicine, American Board of Electrodiagnostic Medicine
• KS License, Kansas Board of Healing Arts
• Neurology, American Board of Psychiatry and Neurology
• Neuromuscular Medicine, American Board of Psychiatry and Neurology

• American Association of Neuromuscular and Electrodiagnostic Medicine, Member, 2017 - Present
• American Academy of Neurology, Member, 2007 - Present

---

Research

Overview

As an active researcher, Dr. Farmakidis is involved in neuromuscular studies as well as engages in sponsor-initiated multicenter myasthenia gravis clinical trials and investigator-initiated studies related to that disease.

• Howard JF, Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ, and the Zilucoplan MG Study Group;, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF, Jr, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jai K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M. 2020. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol
• Farmakidis C, Dimachkie MM, Pasnoor M, Barohn RJ. 2020. Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part II: new and novel agents. Muscle Nerve, 61 (1), 17-25
• Farmakidis C, Dimachkie MM, Pasnoor M, Barohn RJ. 2020. Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part I: traditional agents. Muscle Nerve, 61 (1), 17-25
• Benatar M, Zhang L, Granit V, Statland J, Barohn R, Swenson A, Ravits J, Jackson C, Burns TM, Trivedi J, Pioro EP, Caress J, Katz J, McCauley JL, Rademakers R, Malaspina A, Ostrow LW, Wuu J, CReATe Consortium. 2020. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology, 95 (1), e59-e69
• Mitra R, Raj, Farmakidis C, Pasnoor M, Barohn RJ, Dimachkie MM. 2020. Myasthenia Gravis
• Varon M, Pasnoor M, Farmakidis C, Dimachkie MM. 2019. Nutrition-related peripheral neuropathies. Medlink
• Pasnoor M, Dimachkie MM, Farmakidis C, Barohn RJ, Mitra R. 2019. Disorders of the neuromuscular junction: myasthenia gravis
• Pasnoor M, Dimachkie MM, Farmakidis C, Barohn RJ. 2018. Diagnosis of myathenia gravis. Neurol Clin, 36 (2), 261-274
• Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. 2018. Treatment of myasthenia gravis. Neurol Clin, 36 (2), 311-337
• Farmakidis C, Pasnoor M, Barohn RJ, Dimachkie MM. 2018. Congenital myasthenic syndromes: a clinical and treatment approach. Curr Treat Options in Neurol, 20 (9), 36